Method for preparing acylated crosslinked glycosaminoglycans

Patent metadata

Field	Value
Publication number	US-11939433-B2
Application number	US-202318208527-A
Country	US
Kind code	B2
Filing date	Jun 12, 2023
Priority date	Dec 29, 2015
Publication date	Mar 26, 2024
Grant date	Mar 26, 2024

Abstract

A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

First claim

The invention claimed is:

1. A hydrogel product comprising acylated crosslinked glycosaminoglycans (GAGs), produced by a method comprising:
crosslinking (i) an at least partially deacetylated GAG comprising free amine groups and (ii) a second GAG comprising activated carboxyl groups, by forming amide bonds between 2′-amino groups on the at least partially deacetylated GAG and the activated carboxyl groups of the second GAG,
wherein the hydrogel product has residual free amine groups and a degree of acetylation of at least 95%.

2. The hydrogel product according to claim 1 , wherein the at least partially deacetylated GAG is selected from the group consisting of deacetylated hyaluronic acid, deacetylated chondroitin, and deacetylated chondroitin sulfate, and mixtures thereof.

3. The hydrogel product according to claim 2 , wherein the at least partially deacetylated GAG is deacetylated hyaluronic acid.

4. The hydrogel product according to claim 1 , wherein the at least partially deacetylated GAG has a degree of acetylation of 95% or less, and a weight average molecular weight of 0.1 MDa or more.

5. The hydrogel product according to claim 1 , wherein the at least partially deacetylated GAG is prepared by:
(a) allowing a GAG comprising N-acetyl groups to react with hydroxylamine (NH 2 OH), or a salt thereof, at a temperature of 100° C. or less for 2-200 hours to form the at least partially deacetylated GAG, and
(b) recovering the at least partially deacetylated GAG.

6. The hydrogel product according to claim 1 , wherein the second GAG is selected from the group consisting of hyaluronic acid, chondroitin, and chondroitin sulfate, and mixtures thereof.

7. The hydrogel product according to claim 6 , wherein the second GAG is hyaluronic acid.

8. The hydrogel product according to claim 1 , wherein the activated carboxyl groups on the second GAG are formed using a coupling agent.

9. The hydrogel product according to claim 8 , wherein the coupling agent is a peptide coupling reagent.

10. The hydrogel product according to claim 8 , wherein the coupling reagent is DMTMM.

11. The hydrogel product according to claim 1 , wherein the method of producing the acylated crosslinked GAGs further comprises acetylating residual free amine groups of the crosslinked GAGs.

12. The hydrogel product according to claim 1 , wherein the method of producing the acylated crosslinked GAGs further comprises hydrolyzing ester crosslinks formed as byproducts during the crosslinking by subjecting the crosslinked acetylated GAGs to alkaline solution.

13. The hydrogel product according to claim 12 , wherein the alkaline solution comprises sodium hydroxide or potassium hydroxide.

14. The hydrogel product according to claim 13 , wherein the hydrolyzing is performed in sodium hydroxide solution at a pH of 12 to 14, for 0.5 to 4 hours.

15. The hydrogel product according to claim 1 , wherein the hydrogel product is in a solid, dry form.

16. The hydrogel product according to claim 1 , wherein the at least partially deacetylated GAG has a weight average molecular weight of 0.5 MDa or more.

17. The hydrogel product according to claim 1 , wherein the crosslinked GAGs are substantially free of ester crosslinks.

18. The hydrogel product according to claim 1 , wherein the crosslinked GAGs comprise two different GAGs selected from hyaluronic acid, chondroitin, chondroitin sulphate, heparin sulphate, heparosan, heparin, dermatan sulphate, and keratin sulphate.

19. The hydrogel product according to claim 1 , wherein the second GAG is non-deacetylated.

20. A composition comprising:
the hydrogel product according to claim 1 ; and
water.

Assignees

• Galderma Holding SA
• Galderma Holding S A

Inventors

• Olsson Johan
• Harris Craig Steven

Classifications

• A61K2800/10

  General cosmetic use · CPC title

• A61Q19/00

  Preparations for care of the skin · CPC title

• A61K8/042

  Gels · CPC title

• A61K8/735

  Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof · CPC title

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title